Multidrug-resistant tuberculosis (MDR-TB) poses a significant threat to mankind and as such earned its place on the WHO list of priority pathogens. New antimycobacterials with a mechanism of action different to currently used agents are highly required. This study presents the design, synthesis, and biological evaluation of 3-acylaminopyrazine-2-carboxamides derived from a previously reported inhibitor of human prolyl-tRNA synthetase. Compounds were evaluated in vitro against various strains of mycobacteria, pathogenic bacteria, and fungi of clinical significance. In general, high activity against mycobacteria was noted, while the antibacterial and antifungal activity was minimal. The most active compounds were 4'-substituted 3-(benzamido)pyrazine-2-carboxamides, exerting MIC (Minimum Inhibitory Concentration) from 1.95 to 31.25 µg/mL. Detailed structure-activity relationships were established and rationalized in silico with regard to mycobacterial ProRS as a probable target. The active compounds preserved their activity even against multidrug-resistant strains of Mycobacterium tuberculosis. At the same time, they were non-cytotoxic against HepG2 human hepatocellular carcinoma cells. This project is the first step in the successful repurposing of inhibitors of human ProRS to inhibitors of mycobacterial ProRS with antimycobacterial activity.

Department of Clinical Microbiology University Hospital Hradec Králové Sokolská 581 500 05 Hradec Králové Czech Republic

Faculty of Pharmacy in Hradec Králové Charles University Ak Heyrovského 1203 8 500 05 Hradec Králové Czech Republic

Zobrazit více v PubMed

Mullard A. Tackling antimicrobial drug resistance. Nat. Rev. Drug Discov. 2016;15:375–376. doi: 10.1038/nrd.2016.115. PubMed DOI

Algammal A.M., Hetta H.F., Elkelish A., Alkhalifah D.H.H., Hozzein W.N., Batiha G.E., El Nahhas N., Mabrok M.A. Methicillin-Resistant Staphylococcus aureus (MRSA): One Health Perspective Approach to the Bacterium Epidemiology, Virulence Factors, Antibiotic-Resistance, and Zoonotic Impact. Infect. Drug Resist. 2020;13:3255–3265. doi: 10.2147/IDR.S272733. PubMed DOI PMC

Becker K., Heilmann C., Peters G. Coagulase-negative staphylococci. Clin. Microbiol. Rev. 2014;27:870–926. doi: 10.1128/CMR.00109-13. PubMed DOI PMC

Butler M.S., Gigante V., Sati H., Paulin S., Al-Sulaiman L., Rex J.H., Fernandes P., Arias C.A., Paul M., Thwaites G.E., et al. Analysis of the Clinical Pipeline of Treatments for Drug-Resistant Bacterial Infections: Despite Progress, More Action Is Needed. Antimicrob. Agents Chemother. 2022;66:e0199121. doi: 10.1128/aac.01991-21. PubMed DOI PMC

WHO . Global Tuberculosis Report 2020. World Health Organization; Geneva, Switzerland: 2020.

Ho J.M., Bakkalbasi E., Söll D., Miller C.A. Drugging tRNA aminoacylation. RNA Biol. 2018;15:667–677. doi: 10.1080/15476286.2018.1429879. PubMed DOI PMC

Pang L.P., Weeks S.D., Van Aerschot A. Aminoacyl-tRNA Synthetases as Valuable Targets for Antimicrobial Drug Discovery. Int. J. Mol. Sci. 2021;22:34. doi: 10.3390/ijms22041750. PubMed DOI PMC

Bouz G., Zitko J. Inhibitors of aminoacyl-tRNA synthetases as antimycobacterial compounds: An up-to-date review. Bioorgan. Chem. 2021;110:104806. doi: 10.1016/j.bioorg.2021.104806. PubMed DOI

Adachi R., Okada K., Skene R., Ogawa K., Miwa M., Tsuchinaga K., Ohkubo S., Henta T., Kawamoto T. Discovery of a novel prolyl-tRNA synthetase inhibitor and elucidation of its binding mode to the ATP site in complex with l-proline. Biochem. Biophys. Res. Commun. 2017;488:393–399. doi: 10.1016/j.bbrc.2017.05.064. PubMed DOI

Pang L., Weeks S.D., Juhás M., Strelkov S.V., Zitko J., Van Aerschot A. Towards Novel 3-Aminopyrazinamide-Based Prolyl-tRNA Synthetase Inhibitors: In Silico Modelling, Thermal Shift Assay and Structural Studies. Int. J. Mol. Sci. 2021;22:7793. doi: 10.3390/ijms22157793. PubMed DOI PMC

Jandourek O., Tauchman M., Paterova P., Konecna K., Navratilova L., Kubicek V., Holas O., Zitko J., Dolezal M. Synthesis of Novel Pyrazinamide Derivatives Based on 3-Chloropyrazine-2-carboxamide and Their Antimicrobial Evaluation. Molecules. 2017;22:223. doi: 10.3390/molecules22020223. PubMed DOI PMC

Wamhoff H., Kroth E. Dihalogentriphenylphosphorane in der Heterocyclensynthese, 29. Eine einfache Synthese von Pteridin-4-onen aus 3-Amino-2-pyrazincarbonsäuremethylester und Pyrazino[3,1]oxazin-4-onen. Synthesis. 1994;1994:405–410. doi: 10.1055/s-1994-25487. DOI

Phillips J.C., Hardy D.J., Maia J.D.C., Stone J.E., Ribeiro J.V., Bernardi R.C., Buch R., Fiorin G., Hénin J., Jiang W., et al. Scalable molecular dynamics on CPU and GPU architectures with NAMD. J. Chem. Phys. 2020;153:044130. doi: 10.1063/5.0014475. PubMed DOI PMC

Humphrey W., Dalke A., Schulten K. VMD: Visual molecular dynamics. J. Mol. Graph. 1996;14:33–38. doi: 10.1016/0263-7855(96)00018-5. PubMed DOI

Franzblau S.G., Witzig R.S., McLaughlin J.C., Torres P., Madico G., Hernandez A., Degnan M.T., Cook M.B., Quenzer V.K., Ferguson R.M. Rapid, low-technology MIC determination with clinical Mycobacterium tuberculosis isolates by using the microplate Alamar Blue assay. J. Clin. Microbiol. 1998;36:362–366. doi: 10.1128/JCM.36.2.362-366.1998. PubMed DOI PMC

Juhás M., Pallabothula V.S.K., Grabrijan K., Šimovičová M., Jan’ourek O., Konečná K., Bárta P., Paterová P., Gobec S., Sosič I., et al. Design, synthesis and biological evaluation of substituted 3-amino-N-(thiazol-2-yl)pyrazine-2-carboxamides as inhibitors of mycobacterial methionine aminopeptidase 1. Bioorgan. Chem. 2022;118:105489. doi: 10.1016/j.bioorg.2021.105489. PubMed DOI

Jumper J., Evans R., Pritzel A., Green T., Figurnov M., Ronneberger O., Tunyasuvunakool K., Bates R., Žídek A., Potapenko A., et al. Highly accurate protein structure prediction with AlphaFold. Nature. 2021;596:583–589. doi: 10.1038/s41586-021-03819-2. PubMed DOI PMC

Stumpe M.C., Blinov N., Wishart D., Kovalenko A., Pande V.S. Calculation of Local Water Densities in Biological Systems: A Comparison of Molecular Dynamics Simulations and the 3D-RISM-KH Molecular Theory of Solvation. J. Phys. Chem. B. 2011;115:319–328. doi: 10.1021/jp102587q. PubMed DOI PMC

Wilcken R., Zimmermann M.O., Lange A., Joerger A.C., Boeckler F.M. Principles and Applications of Halogen Bonding in Medicinal Chemistry and Chemical Biology. J. Med. Chem. 2013;56:1363–1388. doi: 10.1021/jm3012068. PubMed DOI

European Committee for Antimicrobial Susceptibility Testing (EUCAST) of the European Society for Clinical Microbiology and Infectious Diseases (ESCMID) EUCAST Discussion Document E. Dis 5.1: Determination of Minimum Inhibitory Concentrations (MICs) of Antibacterial Agents by Broth Dilution. [(accessed on 11 December 2019)];Clin. Microbiol. Infec. 2003 9:1–7. Available online: http://www.eucast.org/documents/publications_in_journals/ PubMed

EUCAST DEFINITIVE DOCUMENT E.DEF 7.3.1. Method for the Determination of Broth Dilution Minimum Inhibitory Concentrations of Antifungal Agents for Yeasts. 2017. [(accessed on 11 December 2019)]. Available online: http://www.eucast.org/astoffungi/methodsinantifungalsusceptibilitytesting/susceptibility_testing_of_yeasts/

EUCAST DEFINITIVE DOCUMENT E.DEF 9.3.1. Method for the Determination of Broth Dilution Minimum Inhibitory Concentrations of Antifungal Agents for Conidia Forming Moulds. 2017. [(accessed on 11 December 2019)]. Available online: http://www.eucast.org/astoffungi/methodsinantifungalsusceptibilitytesting/susceptibility_testing_of_moulds/